Inspire was incorporated in October 1993 and began operations in March 1995. We completed an Initial Public Offering of common stock in August 2000. Inspire's common stock is traded on the Nasdaq Global Market under the ticker symbol "ISPH." We are located in Durham, North Carolina, adjacent to Research Triangle Park.
Inspire was founded based on technology licensed from the University of North Carolina (UNC) at Chapel Hill. Research conducted by a team at UNC's Cystic Fibrosis Research Center led to the discovery that uridine triphosphate (UTP), which is a naturally occurring compound in the body, is capable of increasing airway surface hydration and improving mucociliary clearance through activation of the P2Y receptor.
Inspire scientists, working with UNC researchers, immersed themselves in the emerging field of P2Y receptors, and were soon recognized as leaders in the discovery and synthesis of nucleotides that activate the P2Y2 receptor. Our scientists made and patented many discoveries relating to P2Y2 receptors, their agonists and their potential importance in the treatment of diseases involving deficiencies in the body's natural mechanisms for protecting mucosal surfaces such as the lungs, eyes and sinuses. Based on this technology platform, we have discovered and are developing product candidates for treating dry eye (PROLACRIATM) and cystic fibrosis (denufosol tetrasodium).
In 2004, Inspire licensed several patents for use in developing and commercializing new treatments for glaucoma from the Wisconsin Alumni Research Foundation (WARF). We have developed this research into a unique technology platform and are currently developing two molecules (INS115644 and INS117548) for the treatment of glaucoma.
We have generated a substantial patent portfolio of U.S. patents from our P2Y2 and other research areas.
In late 2003, Inspire built a specialized sales force of 64 representatives dedicated to calling on ophthalmologists, optometrists and allergists in the United States. Our sales force has since grown to approximately 90 representatives that currently promote AZASITE® and also co-promote ELESTAT® through an agreement with Allergan, Inc.
Inspire Announces Webcast of Presentation at BIO CEO Conference
DURHAM, N.C., Feb 04, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
...
Inspire Announces Results of Phase 3 PROLACRIA(TM) Trial for Dry Eye
- Primary and Secondary Endpoints Not Met -DURHAM, N.C., Jan 21, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc...
Inspire Announces Webcast of Presentation at J.P. Morgan Healthcare
Conference
DURHAM, N.C., Jan 07, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Inspir...
Inspire Announces Webcast of Presentation at Piper Jaffray Health Care Conference
DURHAM, N.C.--(BUSINESS WIRE)--Nov. 25, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today...
© Inspire Pharmaceuticals 2010 All Rights Reserved
Terms of Use Legal Notices
Page Updated on: 2/4/2010
